Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1715961 | 1.00 | AR (0.64) | ARNR3C1HDAC1 | |
| SCHEMBL15468237 | 0.93 | AR (0.54) | ARNR3C1HDAC1 | |
| SCHEMBL20003451 | 0.91 | AR (0.52) | ARNR3C1HDAC1 | |
| SCHEMBL547082 | 0.91 | AR (0.76) | ARNR3C1HDAC1 | |
| SCHEMBL30184873 | 0.91 | AR (0.76) | ARNR3C1HDAC1 | |
| SCHEMBL2633035 | 0.88 | AR (0.63) | ARNR3C1HDAC1 | |
| SCHEMBL1715648 | 0.88 | AR (0.75) | ARNR3C1HDAC1 | |
| SCHEMBL30184901 | 0.88 | AR (0.75) | ARNR3C1HDAC1 | |
| SCHEMBL547406 | 0.88 | AR (0.65) | ARNR3C1 | |
| SCHEMBL547047 | 0.88 | AR (0.75) | ARNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003328-A | Diaryl hydantoin compounds | 加利福尼亚大学董事会 | 2023-04-25 | — | — | CN | disclosed |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| CN-110003114-B | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2023-01-17 | — | — | CN | disclosed |
| EP-3970721-A1 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885NR3C1 765/4885HDAC1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.